• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多种药物联合治疗原发性高血压

Multiple drug therapy in the treatment of essential hypertension.

作者信息

Hockenberry B

机构信息

Loyola University Medical Center, Maywood, Illinois.

出版信息

Nurs Clin North Am. 1991 Jun;26(2):417-36.

PMID:2047290
Abstract

Treatment for high blood pressure is aimed to prevent the excess morbidity and mortality associated with hypertension by reducing the blood pressure to acceptable levels and by improving the cardiovascular risk status. Antihypertensive medications can be selected that not only reduce blood pressure but also have beneficial effects in concomitant illness and neutral or positive effects on other cardiovascular risk factors. Multiple drug therapy offers not only the possibility of greater therapeutic efficacy than that achieved with single agents but also the possibility of reduced incidence of side effects through complementary actions. The antihypertensive regimen should be simple and acceptable to the patient to promote compliance. Nurses, along with physicians, have an integral role in the long-term management of hypertensive patients through education, counsel, and follow-up for blood pressure control and health promotion.

摘要

高血压治疗旨在通过将血压降至可接受水平并改善心血管风险状况,预防与高血压相关的过高发病率和死亡率。可以选择不仅能降低血压,而且对伴随疾病有有益作用,对其他心血管危险因素有中性或积极作用的抗高血压药物。联合药物治疗不仅有可能比单一药物取得更大的治疗效果,而且有可能通过互补作用降低副作用的发生率。抗高血压治疗方案应简单且患者能够接受,以促进依从性。护士与医生一道,在高血压患者的长期管理中,通过教育、咨询以及对血压控制和健康促进的随访,发挥不可或缺的作用。

相似文献

1
Multiple drug therapy in the treatment of essential hypertension.多种药物联合治疗原发性高血压
Nurs Clin North Am. 1991 Jun;26(2):417-36.
2
The future of antihypertensive treatment.抗高血压治疗的未来。
Am J Ther. 2007 Mar-Apr;14(2):121-34. doi: 10.1097/01.pap.0000249915.12185.58.
3
ESH-ESC guidelines for the management of hypertension.欧洲高血压学会(ESH)和欧洲心脏病学会(ESC)高血压管理指南
Herz. 2006 Jun;31(4):331-8. doi: 10.1007/s00059-006-2829-3.
4
Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.尼日利亚一家三级医院高血压药物治疗的趋势变化:对新旧抗高血压药物的疗效、安全性、合理性和药物经济学的真实世界评估
J Hum Hypertens. 2003 Apr;17(4):277-85. doi: 10.1038/sj.jhh.1001538.
5
Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients.新诊断高血压患者的降压药物依从性与心血管疾病发病率
Circulation. 2009 Oct 20;120(16):1598-605. doi: 10.1161/CIRCULATIONAHA.108.830299. Epub 2009 Oct 5.
6
[Treatment strategies in essential arterial hypertension].
Rev Prat. 1999 Mar 1;49(5):520-5.
7
Hypertension in middle-aged men. Management, morbidity and prognostic factors during long-term hypertensive care.中年男性高血压。长期高血压护理中的管理、发病率及预后因素。
Acta Med Scand Suppl. 1985;702:1-79.
8
[Management of patients with hypertension resistant to treatment].[难治性高血压患者的管理]
Rev Prat. 1999 Mar 1;49(5):527-31.
9
Clinical pharmacology of antihypertensive therapy.抗高血压治疗的临床药理学
Semin Nephrol. 2005 Jul;25(4):215-26. doi: 10.1016/j.semnephrol.2005.02.006.
10
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.缬沙坦联合氢氯噻嗪与氨氯地平单药治疗对伴有其他心血管危险因素的高血压患者的疗效及耐受性比较:VAST研究
Clin Ther. 2005 May;27(5):578-87. doi: 10.1016/j.clinthera.2005.05.006.

引用本文的文献

1
In vitro study on the effect of cornin on the activity of cytochrome P450 enzymes.玉米素对细胞色素 P450 酶活性的体外研究。
BMC Complement Med Ther. 2021 May 9;21(1):138. doi: 10.1186/s12906-021-03309-y.
2
Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism.川芎嗪与缬沙坦在大鼠体内的药代动力学相互作用研究及其潜在机制
Pharm Biol. 2020 Dec;58(1):1290-1293. doi: 10.1080/13880209.2020.1859554.